Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Park, K.; Vansteenkiste, Johan; Lee, Ki Hyeong; Pentheroudakis, G.; Zhou, Caicun; Prabhash, Kumar; Seto, Takashi; Voon, Pei Jye; Tan, Daniel S.W.; Yang, James Chih‐Hsin; Wang, J.; Babu, K Govind; Nakayama, Yuko; Alip, Adlinda; Chua, Kevin Lee Min; Cheng, Jason Chia‐Hsien; Senan, Suresh; Ahn, Yong Chan; Kim, T.-Y.; Ahn, Hee Kyung; Peters, Solange; Yoshino, Takayuki; Douillard, Jean-Yves

doi:10.1016/j.annonc.2019.10.026

Cited by 81 publications

(53 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGFR mutations or hyperactivation is common among lung cancer patients. While EGFR TKIs achieved a favorable outcome in EGFR-mutant patients and were recommended as first-line treatment for patients with positive EGFR mutation (20), chemotherapeutics including cisplatin, carboplatin, etoposide and docetaxel were used as the first line of treatment for EGFR-wild-type patients (21). However, the outcome of Figure 4.…”

Section: Discussionmentioning

confidence: 99%

CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells

Yin

Zhang

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

cluster of differentiation 44 (cd44) as a transmembrane glycoprotein is found to be expressed in non-small cell lung cancer (NSCLC), is significantly associated with NSLC progression, metastasis and drug resistance. This study aimed to explore whether CD44 inhibition improves the sensitivity of epidermal growth factor receptor (EGFR) wild-type NSCLC cells to cisplatin and how it affects wild-type EGFR in NSCLC cells. Small interfering RNA was used to knockdown CD44 expression in EGFR wild-type NSCLC cell line H460. Results suggested that CD44 downregulation reduced cell growth, promoted G 0 /G 1 cell cycle arrest and induced cell apoptosis in H460 cells and these effects were evidently enhanced when in combination with cisplatin. Deactivation of EGFR signaling pathway including EGFR phosphorylation and its downstream molecules, targets ERK, AKT1 and SRC which were also observed in CD44-silenced H460 cells with or without EGF stimulation. Furthermore, the CD44 expression level was positively correlated with wild-type EGFR level in human lung adenocarcinoma tissues and CD44 inhibition significantly accelerated the degradation of EGFR, indicating that enhanced sensitivity of H460 cells to cisplatin by downregulation of CD44 might be due to EGFR degradation. This study demonstrated that suppression of CD44 deactivated EGFR signals in NSCLC cells with wild-type EGFR, thereby contributing to the inhibition of cell proliferation and the reinforcement of cisplatin sensitivity. It is suggested that downregulation of CD44 could be a novel potential therapeutic strategy for the treatment of EGFR wild-type NScLc.

show abstract

Section: Discussionmentioning

confidence: 99%

CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells

Yin

Zhang

et al. 2020

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…The characteristics of the CPGs are summarized in Table 1. Seven CPGs were established for SCLC (10-16), 20 for NSCLC (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36), and 22 for lung cancer regardless of histological subtype . The number of published CPGs increased every year, with a total of 22 CPGs published in 2020.…”

Section: Characteristics Of Selected Guidelinesmentioning

confidence: 99%

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Yang¹,

Lü²,

Ma³

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: In recent years, the number of clinical practice guidelines (CPGs) for lung cancer has increased, but the quality of these guidelines has not been systematically assessed so far. Our aim was to assess the reporting quality of CPGs on lung cancer published since 2018 using the International Reporting Items for Practice Guidelines in Health Care (RIGHT) instrument. Methods:We systematically searched the major electronic literature databases, guideline databases and medical society websites from January 2018 to November 2020 to identify all CPGs for small cell and nonsmall cell lung cancer (NSCLC). The search and extraction were completed using standardized forms.The quality of included guidelines was evaluated using the RIGHT statement. We present the results descriptively, including a stratification by selected determinants.Results: A total of 49 CPGs were included. The mean proportion across the guidelines of the 22 items of the RIGHT checklist that were appropriately reported was 57.9%. The items most common to be poorly reported were quality assurance (item 17) and description of the role of funders (item 18b), both of which were reported in only one guideline. The proportions of items within each of the seven domains of the RIGHT checklist that were correctly reported were Basic information 75.9%; background 83.2%; evidence 44.5%; recommendations 55.4%; review and quality assurance 12.2%; funding and declaration and management of interests 42.9%; and other information 38.1%. The reporting quality of guidelines did not differ between publication years. CPGs published in journals with impact factor >30 tended to be best reported. Conclusions:Our results revealed that reporting in CPGs for lung cancer is suboptimal. Particularly the declaration of funding and quality assurance are poorly reported in recent CPGs on lung cancer.

show abstract

“…Multiple guidelines exist and show consensus on the treatment for LA-NSCLC. For example, the newer consensus of Asian societies, shows high concordance with all recommendations of the 2017 ESMO guidelines accepting them as clinical practice guidelines (42). Most guidelines agree that patients with LA-NSCLC need to be discussed in multidisciplinary boards attended by an experienced thoracic surgeon and radiation oncologist and the best treatment remains a matter of debate (8).…”

Section: Current Guidelinesmentioning

confidence: 99%

Management of stage IIIA NSCLC: the role of radiotherapy—a narrative review

Iseli¹,

Süveg²,

Fischer³

et al. 2022

Curr Chall Thorac Surg

View full text Add to dashboard Cite

BackgroundWorldwide, two million patients are newly diagnosed with lung cancer and 1.7 million die of it every year (1). The most relevant risk factor is and remains smoking (2,3). Non-small cell lung cancer (NSCLC) is the most common histology and accounts for up to 85% of lung cancer cases (4). The 8 th edition of the TNM-classification defines stages I to IV, with subgroups to each stage (Table 1) (5). Generally, patients with stage I to III qualify for curative treatment regimens, while stage IV patients undergo palliative treatment-individual exemptions excluded. As symptoms occur late, 20-27% of patients are diagnosed with locally advanced disease (LA-NSCLC-stage III) (6,7). Patients with LA-NSCLC show large variety of primary tumour extent or lymph node (LN) involvement and are all staged as IIIA-C. Especially within stage III N2 disease, the patient collective shows considerable heterogeneity, leading to different treatment options. Main multimodal treatment options are surgery with (neo)adjuvant chemotherapy or neoadjuvant chemoradiotherapy (CRT) or definitive CRT with or without immunotherapy (IT) (8). Nevertheless, overall survival (OS) remains poor for LA-

show abstract

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Cited by 81 publications

References 57 publications

CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells

CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells

Evaluation of the reporting quality of clinical practice guidelines on lung cancer using the RIGHT checklist

Management of stage IIIA NSCLC: the role of radiotherapy—a narrative review

Contact Info

Product

Resources

About